![](https://monteverdelaw.com/wp-content/uploads/RVNC_BIG-2d064c44.png)
Revance Therapeutics, Inc. (Nasdaq: RVNC), relating to its proposed merger with Crown Laboratories, Inc. Under the terms of the agreement, Revance shareholders will receive $6.66 in cash per share they own.
Revance Therapeutics, Inc. (Nasdaq: RVNC), relating to its proposed merger with Crown Laboratories, Inc. Under the terms of the agreement, Revance shareholders will receive $6.66 in cash per share they own.